Keymed Biomedical Technology

Keymed Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative biological therapies for autoimmune and oncology indications. The company leverages its proprietary nTCE bispecific antibody platform and high-throughput screening capabilities to build a robust pipeline of differentiated drug candidates. Its lead product, Stapokibart (CM310), is an IL-4Rα antagonist that recently received approval in China for the treatment of moderate-to-severe atopic dermatitis. Keymed has established significant global partnerships, most notably a licensing agreement with AstraZeneca for its Claudin 18.2-targeting antibody-drug conjugate, CMG901. With integrated capabilities from research to commercial-scale GMP manufacturing, the company is well-positioned to address significant unmet medical needs globally.